Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is standard of care for muscle-invasive bladder cancer (MIBC). However, NAC is used in less than 20% of patients with MIBC.
Clinical trials often fail to reach their anticipated end points, most frequently because of poor accrual. Prior studies have analyzed trial termination, but it has not been easy to assess accrual estimates using international databases such as ClinicalTrials.
Patient enrollment now underway in Phase 3 SPOTLIGHT as well as LIGHTHOUSE clinical trials in prostate cancer San Francisco, CA (UroToday.com) — Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced that the first patients have been dosed at clinical trial sites in its Phase 3 SPOTLIGHT clinical trial of rhPSMA-7.3 […]
Expanded research program and revolutionary, inexpensive, non-invasive test to assess genetic risk of prostate cancer is in development San Francisco, CA (UroToday.com) – The Prostate Cancer Foundation (PCF) and Robert F. Smith, founder, chairman and CEO of Vista Equity Partners, announce a new effort to reduce deaths from prostate cancer, one of the largest health disparities […]
As a prime example of international and cross-institutional cooperation, the working group. ‘Reproductive Genetics’ (AG Reproduktionsgenetik) succeeded in identifying a new gene named to be causative in male infertility. The results of extensive M1AP-related research, led by Margot Wyrwoll, Corinna Friedrich, and Frank Tüttelmann (Institute of Human Genetics, University of Münster) have recently been published […]
{{header-clinical-trials-navigation}} A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy. Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04186845 Sponsor: Blue Earth Diagnostics Phase: Phase 3 […]
Serum prostatic specific antigen (PSA) and serum testosterone levels share an undefined relationship with each other, with many conflicting studies showing both positive and negative correlation between them.
To develop and validate survival nomograms for predicting the overall survival (OS) and cancer-specific survival (CSS) in upper tract urothelial carcinoma (UTUC) patients. Patients diagnosed with UTUC from 2010 to 2015 in the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively enrolled.
[223Ra]RaCl2 is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [223Ra]RaCl2 is excreted via the intestine into feces, and some is absorbed from the intestine into the blood, which may be undesirable in terms of the exposure to radiation.
To investigate the value of using contrast-enhanced transrectal ultrasound (CETRUS) to reduce unnecessary collection of biopsies during prostate cancer diagnosis and its utility in predicting biochemical recurrence in patients with localized prostate cancer.
